Find Peptide Clinics
Clinic partner placement is available in select cities.View listing options

Sermorelin Side Effects: The Label That Left the Shelf

Find Peptide Clinics Editorial Desk

Sermorelin side effects are the most repeated claim in peptide marketing and the least documented fact in the US drug record, because the only approved sermorelin product was taken off the market and the FDA put nothing in its place. The short answer, from the primary record: in the approved era the common harms were a hot face and a sore injection site, and today the real risk sits in an unapproved bulk powder that arrives with no prescribing information at all.

Sermorelin Side Effects From the Approved Era: Flushing and a Sore Spot

Sermorelin is a 29 amino acid analogue of human growth hormone releasing hormone, the shortest synthetic peptide that carries full GHRH activity, according to the review by Andrew Prakash and Karen Goa published in BioDrugs in August 1999 (12(2):139-157). Those two reviewers read the trial file and compressed the safety record into one sentence. Single intravenous doses and repeated nightly subcutaneous doses were well tolerated. Transient facial flushing and pain at the injection site were the most commonly reported adverse events.

The intravenous diagnostic dose was 1 microgram per kilogram of bodyweight. The subcutaneous treatment dose in children was 30 micrograms per kilogram at bedtime, once a day. Those are the numbers a prescriber had in 1999, printed on a label, with a company phone number on the carton.

The FDA Record: Approved in 1990, Discontinued, and Not Pulled for Harm

The FDA’s own drug database settles the regulatory question in a way no clinic page does. Application NDA 019863 for Geref, sermorelin acetate for injection, carries an original approval dated 28 December 1990. A second application, NDA 020443, covers the 0.5 milligram and 1 milligram vials, with a submission dated 26 September 1997. Both records now list the marketing status as Discontinued.

The same record carries a line that peptide sellers rarely quote. FDA notes a Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons.

That distinction matters for anyone weighing risk. The FDA note says the product was not discontinued or withdrawn for safety or effectiveness reasons, and the record does not state why the sponsor stopped marketing it. Nothing here depends on the reason: the 1999 trial file is the published safety record for the approved product, which is why it carries the weight in this piece.

The FDA application record above was retrieved on 21 October 2026.

No Current Label Exists, and That Is Verifiable

Search the National Library of Medicine’s DailyMed repository for sermorelin on 22 October 2026 and the service returns zero labeling records. Query the FDA’s openFDA label endpoint for the generic name and it returns no matches.

A patient who asks what the current US prescribing information says about sermorelin gets a blank page. The drug exists in the supply chain. The instructions do not exist in public.

The FDA’s National Drug Code directory shows what is sold today: 17 sermorelin entries, and each one is a bulk ingredient powder. Medisca, Letco Medical, Darmerica, Willow Birch Pharma and a group of overseas manufacturers list it as bulk ingredient for human prescription compounding. Not one entry is a finished patient product with an approved label.

A clinic writing a sermorelin prescription in 2026 is writing for a compounded preparation. FDA’s records show no approved finished sermorelin product to dispense, and the compounded vial carries no approved prescribing information. That is a different regulatory object from a drug approved for a condition, and the difference lands on the patient as an absence of dosing guardrails.

Sermorelin Side Effects in Older Adults: One Trial, One Adverse Event

The anti-aging market sells sermorelin to people in their fifties and sixties. The published randomized data in that age group is thin, and one trial carries most of it.

Omid Khorram, Grace Laughlin and Samuel Yen ran a single blind, randomized, placebo controlled trial published in the Journal of Clinical Endocrinology and Metabolism in May 1997 (82(5):1472-1479). Nineteen people, 10 women and 9 men, aged 55 to 71, injected saline nightly for four weeks, then a GHRH(1-29) analogue at 10 micrograms per kilogram nightly for 16 weeks.

The reported result deserves precision. The only adverse side effect was transient hyperlipidemia, which resolved by the end of the study. Skin thickness rose in both sexes. Lean body mass, insulin sensitivity, general well being and libido rose in the men and not in the women.

One caveat a careful reader should hold: the peptide in that trial was [Nle27]GHRH-(1-29)-NH2, a GHRH analogue one residue away from sermorelin acetate. Close family, not the identical molecule. Anyone quoting that trial as sermorelin proof is stretching it, and anyone quoting it as sermorelin harm is stretching it in the other direction.

IGF-1: The Number to Watch, From 14 Men and Three Shots a Day

Growth hormone releasing hormone does one measurable thing well. It pushes the pituitary to release growth hormone, which raises insulin like growth factor 1. That rise is the effect patients pay for and the effect a monitoring plan should track.

A retrospective chart review by Jason Sigalos and colleagues, published in the American Journal of Men’s Health in November 2017 (11(6):1752-1757), looked at 105 men on testosterone therapy who were prescribed 100 micrograms each of GHRP-6, GHRP-2 and sermorelin three times daily. Fourteen met strict inclusion criteria. Mean IGF-1 at baseline was 159.5 nanograms per milliliter. After a mean 134 days of continuous treatment it was 239.0.

That is a real shift in a hormone axis, and it is exactly why a clinic has to measure IGF-1 before and during treatment. The review design carried no adverse event endpoint, so it tells you the axis moved and says nothing about what else moved.

The 2026 Reviews: Prolactin, Cortisol, Fluid, Blood Sugar

Two narrative reviews published this year pulled the grey market evidence together, and both land on the same warning.

Dominikowski and colleagues, writing in Frontiers in Endocrinology in 2026 (17:1822475), list the reported adverse effects across GH and IGF-1 peptides: prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention, myalgia and arthralgia, and injection site reactions. They note the absence of regulatory approval for physique or performance indications and the uncertainty around product composition, dose and stacking in unregulated supply chains.

Mendias and Awan, in Sports Medicine in August 2026 (56(8):1921-1935), put the same problem plainly: many unapproved peptides show favorable tissue outcomes in animals, rigorous human safety data are scarce, and serious harm remains possible.

Sinha and colleagues had already said it in Translational Andrology and Urology in 2020 (9 Suppl 2:S149-S159): growth hormone secretagogues reliably raise GH and IGF-1, and clinical data on what that does for patients remain lacking.

None of that says sermorelin harms people. It says the evidence base for the version sold today is built on animal work, small retrospective chart reviews and marketing copy, and the safety net that a label provides is absent.

What Compounding Changed, and What It Costs a Patient

A patient can buy a compounded sermorelin powder dosed from a clinic protocol that no regulator reviewed, at a monthly price the clinic sets. For what the current market charges, see our breakdown of what compounded sermorelin costs and the fee questions worth asking before signing.

The comparison that matters is sermorelin against a monitoring plan: baseline IGF-1, a repeat at a defined interval, a provider who will stop the protocol when the number or the symptom says stop, and a written answer to what happens if a batch is misdosed.

Our wider review of peptide side effects and the FDA safety list covers how the agency has handled this class, molecule by molecule.

Questions to Ask Before You Pay for Sermorelin

  • Which pharmacy compounds this, and can I see its state license and its sterility testing?
  • What is my baseline IGF-1, and what is the target range you are dosing toward?
  • Which published trial supports the dose on this protocol, and what was the duration?
  • What symptoms end the protocol, and who answers the phone at 9pm if one appears?
  • Is this billed as a prescription with a diagnosis code, or as a wellness product outside insurance?

A clinic that answers those five in writing is a different business from one that answers with a video.

Frequently asked questions

What are the most common sermorelin side effects?

Transient facial flushing and pain at the injection site, per the 1999 BioDrugs review of the approved product’s trial file.

Is sermorelin FDA approved today?

No finished sermorelin product holds a current FDA approval. Geref, the only approved version, shows as discontinued in the FDA application record, and the agency noted the withdrawal came for reasons other than safety or effectiveness.

Does sermorelin have a current FDA label?

No. DailyMed returned zero sermorelin labeling records on 22 October 2026, and the FDA’s openFDA label endpoint returned no matches for the generic name.

Can sermorelin raise IGF-1?

Yes, in the limited human data available. A 2017 retrospective review of 14 men on sermorelin with two other secretagogues reported mean IGF-1 rising from 159.5 to 239.0 nanograms per milliliter over a mean 134 days.

Was sermorelin tested in older adults?

Once, in a small randomized trial published in 1997: 19 people aged 55 to 71, 16 weeks of a GHRH analogue at 10 micrograms per kilogram nightly, with transient hyperlipidemia as the only reported adverse effect.

What serious risks do the 2026 reviews flag?

Prolactin and cortisol elevations, dysglycaemia, fluid retention, joint and muscle pain, all compounded by uncertain product composition in unregulated supply.

Is compounded sermorelin the same as Geref?

No. Geref was a finished, approved vial. What clinics dispense now is a compounded preparation from bulk powder, which FDA does not approve as a drug.

Sources

This article is reporting on published labels and trial results for a directory of clinics and patients. It is not medical advice, and it does not tell anyone what to take.